Shares of MyoKardia, Inc. (NASDAQ:MYOK) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $43.25.

MYOK has been the subject of a number of analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $32.00 price target on shares of MyoKardia in a research report on Wednesday, May 10th. Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. TheStreet lowered MyoKardia from a “c-” rating to a “d+” rating in a research report on Friday, May 19th. BidaskClub raised MyoKardia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $48.00 price target (up from $31.00) on shares of MyoKardia in a research report on Monday, August 7th.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/12/myokardia-inc-nasdaqmyok-given-average-recommendation-of-buy-by-brokerages.html.

In other MyoKardia news, insider Joseph Lambing sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $30.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now owns 119,718 shares in the company, valued at approximately $3,591,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anastasios Gianakakos sold 4,300 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $16.62, for a total value of $71,466.00. Following the completion of the transaction, the chief executive officer now owns 512,463 shares of the company’s stock, valued at approximately $8,517,135.06. The disclosure for this sale can be found here. Insiders sold a total of 67,288 shares of company stock valued at $1,441,236 in the last 90 days. Corporate insiders own 46.10% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nationwide Fund Advisors increased its position in shares of MyoKardia by 36.3% in the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after buying an additional 2,591 shares during the period. Highbridge Capital Management LLC acquired a new position in shares of MyoKardia during the first quarter worth about $136,000. Alliancebernstein L.P. acquired a new position in shares of MyoKardia during the second quarter worth about $148,000. State of Wisconsin Investment Board acquired a new position in shares of MyoKardia during the second quarter worth about $157,000. Finally, Daiwa SB Investments Ltd. acquired a new position in shares of MyoKardia during the first quarter worth about $170,000. Hedge funds and other institutional investors own 47.74% of the company’s stock.

MyoKardia (MYOK) traded up 2.37% during trading on Friday, reaching $36.70. 1,210,081 shares of the company’s stock were exchanged. The firm’s market cap is $1.16 billion. MyoKardia has a 12 month low of $10.55 and a 12 month high of $37.88. The firm’s 50-day moving average price is $17.34 and its 200-day moving average price is $14.04.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.04. The company had revenue of $5.60 million during the quarter, compared to analysts’ expectations of $6.73 million. MyoKardia had a negative net margin of 44.65% and a negative return on equity of 16.35%. The company’s quarterly revenue was up 60.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.37) earnings per share. On average, equities research analysts anticipate that MyoKardia will post ($1.64) EPS for the current year.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.